Overview

ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen. The main efficacy criteria will be the change in mean Systolic Blood Pressure (SBP), measured at doctor's office with an automatic device, after a 10-week treatment period in hypertensive patients insufficiently controlled by monotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Hydrochlorothiazide
Irbesartan